Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Bruno Paiva, PhD, María Belén Vidriales, Maria Desamparados Sampere Talens, Fabian Tarin, Enrique Colado, Celina Benavente, María Teresa Cedena, MD, Joaquin Sanchez, MD, Teresa Caballero-Velázquez, MD PhD, Lourdes Cordon, David Martínez-Cuadron, MD, Teresa Bernal del Castillo, MD PhD, Carmen Botella, Sofia Grille, MDPhD, Josefina Serrano, MD, Carlos Rodriguez, Jesús Lorenzo Algarra, Juan Manuel Alonso Dominguez, MD PhD MSc, Maria Luz Amigo, MD, Manuel BARRIOS García, MDPhD, Raimundo García-Boyero, MD, Mercedes Colorado, MD, Jaime Perez De Oteyza, MDPhD, Manuel Perez Encinas, MD, Lissette Del Pilar Costilla, MD, Maria Jose Sayas, Olga Pérez-López, Marcos González, Jose A. Perez-Simon, MD PhD, Joaquin Martinez-Lopez, MD PhD, Claudia Lucia Sossa, Alberto Orfao, MD PhD, Jesús F. San-Miguel, Miguel Sanz, MD PhD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-134349

Published: 2020

Journal Articles

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Pilar Martínez, MD, Tomás Palanques Pastor, Jose Luiz Lopez Lorenzo, MD, Javier Cornago Navascués, MD, Gabriela Rodriguez-Macías, MD, Isabel Cano, MD, Montserrat Arnan Sangerman, María-Belén Vidriales, MDPhD, Jesús Lorenzo Algarra, Maria Angeles Foncillas, Pilar Herrera Puente, Carmen Botella, Susana Vives, MD, Angela Figuera Alvarez, MD PhD, Laida Cuevas Palomares, Marta Sobas, MDPhD, Alejandro Contento-Gonzalo, MD, Rebeca Cuello, MD, María Elena Amutio Diez, MD, Maria Dunia De Miguel, MD, Begoña Navas, MD, Juan Miguel Bergua Burgues, MD, Teresa Bernal del Castillo, MD PhD, María Carmen Mateos Rodríguez, MD, Erik de Cabo López, MD, Ana Carolina Franco Villegas, MD, Raimundo García-Boyero, MD, Cristian Escolano Escobar, MD, Cristina Seri, MD, Carlos Cervero, MD, Alicia Roldán Pérez, Maria Lourdes Hermosin, MD, Marta Cervera, MD, María Teresa Olave, MD, Paola Sandra Villafuerte Gutierrez, MD, Almudena De Laiglesia, MD, Josefina Serrano, MD, María Josefa Najera Irazu, MD, Jose Luis Piñana Sanchez, Miguel Ángel Sanz, MD, Joaquin Martinez-Lopez, MD, Pau Montesinos, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138471

Published: 2020

Journal Articles

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Blood (2020) 136 (Supplement 1): 25–27.

https://doi.org/10.1182/blood-2020-141213

Published: 2020

Journal Articles

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-137383

Published: 2020

Journal Articles

Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Genetic Mutations

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139588

Published: 2020

Journal Articles

Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes

Blood (2019) 134 (Supplement_1): 4226.

https://doi.org/10.1182/blood-2019-127204

Published: 2019

Journal Articles

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Blood (2019) 134 (Supplement_1): 1321.

https://doi.org/10.1182/blood-2019-128568

Published: 2019

Journal Articles

Strategy for Identification of an Inherited Leukemia Predisposition in a 299 Patients Cohort with Tumor-Only Sequencing Data

Almudena Aguilera Díaz, MSc, BS, Sara Palomino-Echeverria, MSc, BSc, Iria Vazquez, PhD BSc, Beñat Ariceta, BSc, Maria Jose Larrayoz, BSc, Amagoia Mañu, BSc, Zuriñe Blasco-Iturri, MSc, BSc, Matxalen Olivares Salaverri, MD, Maria Teresa Olave Rubio, MD, Teresa Bernal Del Castillo, MD PhD, Jose J. Rifon Roca, MD, Ana Alfonso Pierola, MD PhD, Felipe Prosper, MD PhD, Marta Fernández-Mercado, PhD MSc, BSc, Maria Jose Calasanz, PhD BSc

Blood (2019) 134 (Supplement_1): 1415.

https://doi.org/10.1182/blood-2019-126634

Published: 2019

Journal Articles

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Lisa Pleyer, Michael Leisch, MD, Alexandra Kourakli, MD PhD, Eric Padron, MD, Jaroslaw P. Maciejewski, MD PhD, Blanca Xicoy, MD MSc, Jennifer Kaivers, MD, Johanna Ungerstedt, MD PhD, Sonja Heibl, MD, Peristera Patiou, MD, Anthony M. Hunter, MD, Elvira Mora, MD, Klaus Geissler, MD, Maria Dimou, MD PhD, María-José Jimenez, MD, David Kiesl, MD, Nora-Athina Viniou, MD PhD, Bhumika J. Patel, MD, Montserrat Arnan Sangerman, Peter Valent, MD, Christoforos Roubakis, MD, Teresa Bernal del Castillo, MD PhD, Athanasios Galanopoulos, MD PhD, Marisa Calabuig, MD, Nicolas Bonadies, MD, Antonio Medina de Almeida, MD PhD, Jaroslav Cermak, MD PhD, Andres Jerez, Julia Montoro, MD, Albert Cortés, Alejandro Avendaño Pita, MD, Bernardo López Andrade, MD, Eva Hellstrom Lindberg, MD PhD, Ulrich Germing, MD, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Argiris Symeonidis, MD PhD, Guillermo F. Sanz, MD PhD, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 844.

https://doi.org/10.1182/blood-2019-123941

Published: 2019

Journal Articles

Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction

Blood (2018) 132 (Supplement 1): 4339.

https://doi.org/10.1182/blood-2018-99-116045

Published: 2018

Journal Articles

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 4363.

https://doi.org/10.1182/blood-2018-99-110210

Published: 2018

Journal Articles

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Jordi Esteve, MD PhD, Rik Schots, Teresa Bernal Del Castillo, MD PhD, Je-Hwan Lee, MD PhD, Eunice S. Wang, MD, Shira Dinner, MD, Mark D. Minden, MD PhD, Olga Salamero, MD, Jorge Sierra, MD, Goichi Yoshimoto, MD PhD, Kamel Laribi, MD, Janusz Halka, MD, Pau Montesinos, MD PhD, Shufang Liu, Elizabeth Shima Rich, MD PhD, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 2736.

https://doi.org/10.1182/blood-2018-99-110976

Published: 2018

Journal Articles

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Blood (2018) 132 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2018-99-111883

Published: 2018

Journal Articles

Preexisting Mutations in Hematopoietic Stem Cells in Patients with Therapy-Related Myeloid Neoplasms

Blood (2017) 130 (Supplement 1): 3956.

https://doi.org/10.1182/blood.V130.Suppl_1.3956.3956

Published: 2017

Journal Articles

Long-Term Results and Cost-Effectiveness of the Flagida-Lite Regimen in Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Almudena Cabero Martínez, Arancha Bermudez, Lucrecia Yañez, Andrés Insunza, Mercedes Araujo Colorado, PhD, Cristina Fernandez Martinez, Virginia Martinez Callejo, Teresa Bernal Del Castillo, MD PhD, Miriam Sánchez Escamilla, Mónica López Duarte, German Pérez Vázquez, Carmen Montes, Eulogio Conde, MD PhD, Maria Luisa Gutiérrez, Sara García Ávila, Mara Celis, Carlos Richard

Blood (2017) 130 (Supplement 1): 2614.

https://doi.org/10.1182/blood.V130.Suppl_1.2614.2614

Published: 2017

Journal Articles

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Hartmut Döhner, MD, Paresh Vyas, MD PhD, John F. Seymour, MD, Valeria Santini, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Haifa Kathrin Al-Ali, MD, Teresa Bernal del Castillo, MD PhD, John Morrill, MS, Stephen Songer, PharmD, Jerry Weaver, PhD, Barry S. Skikne, MD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 1638.

https://doi.org/10.1182/blood.V128.22.1638.1638

Published: 2016

NARROW

Impact of Measurable Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC): A Real-World Study in 1,076 Patients with Acute Myeloid Leukemia (AML)

Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Genetic Mutations

Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Strategy for Identification of an Inherited Leukemia Predisposition in a 299 Patients Cohort with Tumor-Only Sequencing Data

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Preexisting Mutations in Hematopoietic Stem Cells in Patients with Therapy-Related Myeloid Neoplasms

Long-Term Results and Cost-Effectiveness of the Flagida-Lite Regimen in Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only